株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

敗血症治療薬の世界市場

Sepsis Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 210344
出版日 ページ情報 英文 79 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.74円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
敗血症治療薬の世界市場 Sepsis Therapeutics
出版日: 2019年01月01日 ページ情報: 英文 79 Pages
概要

当レポートでは、世界の敗血症治療薬市場について調査分析を行い、米国および世界のその他の諸国の各市場について分析し、今後の市場予測、主要企業のプロファイルなどについてまとめています。

第1章 イントロダクション、調査方法、製品の定義

第2章 エグゼクティブサマリー

  • 産業の概要
    • 敗血症治療薬のイントロダクション
    • 敗血症専用治療薬の不在
    • 開発中止または市場撤退した敗血症治療薬候補
    • 競合とパイプライン
    • 現在の敗血症の第一療法で使われる抗生物質のカテゴリー
    • 主なパイプラン薬:2016年
    • 現在と将来の分析
    • 成長促進因子
    • 市場抑制因子
    • 臨床試験戦略の見直しの必要性
    • 新たな免疫の作用機構に注目
    • 薬物耐性の脅威
    • 高齢者人口統計
  • 敗血症治療薬の革新
  • 敗血症の概要
  • 臨床試験
  • 製品の導入と承認
  • 最近の産業活動
  • 世界の主要企業
    • Adrenomed AG (ドイツ)
    • AM-Pharma B.V. (オランダ)
    • Aridis Pharmaceuticals, Inc. (米国)
    • Asahi Kasei Pharma America (米国)
    • Astellas Pharma Inc. (日本)
    • Bristol-Myers Squibb Company (米国)
    • Chong Kun Dang BiO Corp. (韓国)
    • Endacea, Inc. (米国)
    • InflaRx GmbH (ドイツ)
    • Opsona Therapeutics Ltd. (アイルランド)
    • Opsonix, Inc. (米国)
    • T2 Biosystems, Inc. (米国)
    • TaiRx, Inc. (米国)
    • TiGenix NV (ベルギー)
  • 世界市場の概要

第3章 市場

  • 米国
  • 世界のその他の諸国
目次
Product Code: MCP-6525

This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2024. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -

Adrenomed AG
AM-Pharma B.V
AMOMED Pharma GmbH
Asahi Kasei Pharma America
Endacea, Inc.
InflaRx N.V.

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW

  • Sepsis - A Prelude
  • New Treatment Protocols and New Definitions - Every Minute Counts!!
  • Aging Population: A Key Growth Driver for Sepsis Therapeutics
    • Table 1: Global Population Statistics for the 60+ Age Group (2017E) (includes corresponding Graph/Chart)
    • Table 2: Global Population by Age Group: Percentage-wise Breakdown for Different Age Groups for Years 2017, 2050, and 2100 (includes corresponding Graph/Chart)
    • Table 3: Global Population Statistics for the 60+ Age Group by Region (2017)
    • Table 4: Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)
  • Antibiotics and Vasopressors - The Current Standard of Care
  • Current Categories of Antibacterial Agents for First-line Sepsis Treatment
  • Current Anti-bacterial Drugs used in Sepsis
  • Current Antifungals used for Sepsis
  • Current Antivirals used for Sepsis
  • GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
  • Argipressin Gains Approval for Septic Shock in 26 EU countries
  • Current & Future Analysis
  • Growth Drivers in a Nutshell
  • Market Restraints

3. MARKET DYNAMICS

  • A Market Characterized by High Unmet Medical Needs
  • Research Activity Enables Increased Awareness of Disease Pathogenesis
  • Select Sepsis Therapeutics under Phase IV Clinical Trials: As of 2018
  • Select Sepsis Therapeutics under Phase III Clinical Trials: 2018
  • Novel Immune-Specific Modes of Action under Focus
  • Emphasizing on Endothelial Cell Function
  • HMGB1- A Potential Target for Future Therapies
  • Nanoparticle Systems Demonstrate Potential for Use in Septic Shock Management
  • Researchers Employ IL-7 to Increase CD4 and CD8 Immune Cells in Patients
  • Hydrocortisone Displays Potential in Septic Shock Treatment
  • Reduced Levels of Vitamin C Characterize Sepsis Patients
  • Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
  • Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
  • Researchers Develop ss-Sepsis-3 Protocol for Evaluation of Sepsis in Animal Models
  • World Sepsis Day Aims to Result in Improvement in Sepsis Management
  • NSAIDs Demonstrate Potential to Treat Sepsis

4. SEPSIS: AN OVERVIEW

  • Sepsis - A Major Life-Threatening Condition
  • Risk Profile
  • Most Vulnerable Groups: Newborns and the Elderly
  • A Growing Threat in Hospital Environment
  • Types of Sepsis
  • SIRS
  • Uncomplicated Sepsis
  • Severe Sepsis
  • Septic Shock
  • Septicemia
  • Bacteremia
  • Mortality Rates
  • Mortality Rate on a Decline
  • Hospital Re-Admission Rate Remains High
  • Symptoms to Identify Sepsis Patients
  • General Symptoms in Sepsis Patients
  • Symptoms Specific to Source of Infection
  • Biological Changes in Sepsis Patients
  • Organ Dysfunction Symptoms in Acute Cases
  • Common Sources of Sepsis
  • Stages of Sepsis' Progression
  • Treatment of Sepsis
  • General Approaches for Treatment of Severe Sepsis and Septic Shock
  • Overview of Traditional Treatment Approaches
  • Anti-microbials
    • Drug Resistance: The Major Threat to Sepsis Standby Antibiotics
  • Vasopressors
  • Corticosteroids
  • Immunoglobulins
  • Anticoagulants
  • Neonatal Sepsis

5. COMPETITIVE LANDSCAPE

  • 5.1 Focus on Select Global Players
  • Adrenomed AG (Germany)
  • AM-Pharma B.V. (Netherlands)
  • AMOMED Pharma GmbH (Austria)
  • Asahi Kasei Pharma America (USA)
  • Endacea, Inc. (USA)
  • InflaRx N.V. (Germany)
  • La Jolla Pharmaceutical Company (USA)
  • TaiRx, Inc. (USA)
  • 5.2 Product Introductions/Approvals
  • Asahi Kasei Pharma Obtains Phase III Clinical Study Results for ART-123
  • Argipressin Receives Approval in 26 EU Countries
  • La Jolla Pharmaceutical Receives FDA Approval for Giapreza Injection
  • Sepsis Alliance Partners with La Jolla Pharmaceutical

6. GLOBAL MARKET PERSPECTIVE

    • Table 5: World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region/Country - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2024 (includes corresponding Graph/Chart)
    • Table 6: World 5-Year Perspective for Sepsis Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2018, 2021, and 2024 (includes corresponding Graph/Chart)

7. REGIONAL MARKET PERSPECTIVE

  • 7.1 The United States
  • A. Market Analysis
    • United States: The Largest Market for Sepsis Therapeutics
    • Alarming Incidence of Sepsis & Lack of Therapies
    • Table 7: Estimated Annual Incidence of Septic Shock in the US (2016 - 2022E) (includes corresponding Graph/Chart)
    • Aging Population: A Key Growth Factor
    • Table 8: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 9: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 10: The US Recent Past, Current & Future Analysis for Sepsis Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2024 (includes corresponding Graph/Chart)
  • 7.2 Rest of World
  • A. Market Analysis
    • Aging Population: Key Opportunity Indicator
    • Table 11: Aging Population in Canada (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 12: Aging Population in Europe by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • India
      • India: High Incidence of Neonatal Sepsis
    • Table 13: Estimated Incidence and Mortality Associated with AIDS, Breast Cancer, MI, and Sepsis in India (includes corresponding Graph/Chart)
      • Key Opportunity Indicator: Aging Population Statistics in Rest of World
    • Table 14: Aging Population in Asia-Pacific by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 15: Aging Population in Latin America by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 16: Aging Population in the Middle East by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 17: Aging Population in Africa by Region (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 18: Rest of World Recent Past, Current & Future Analysis for Sepsis Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2024 (includes corresponding Graph/Chart)

8. COMPANY PROFILES

  • Total Companies Profiled: 24 The United States (7) Canada (3) Japan (1) Europe (8) - France (1) - Germany (4) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (4) Middle East (1) SEPSIS THERAPEUTICS MCP-6525 CONTENTS
Back to Top